Onco Actu du 5 juillet 2019

	2.6 ETIOLOGIE - ENVIRONNEMENT
Sydney's city council reviews use of Bayer's Roundup weed killer amid cancer fears [Reuters] The prospect of Sydney council rethinking its ties to Roundup, a flagship product of U.S. agribusiness giant Monsanto Co until a buyout from Bayer last year, shows the pressure that grassroots campaigns and lawsuits are putting on governments about the product even as regulators declare it safe.
	4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC
Sports playbook helps doctors predict cancer patient outcomes [Stanford Medicine] Surprisingly, the researchers have also found that the approach, which they’ve termed CIRI for Continuous Individualized Risk Index, may also help doctors to pinpoint people who might benefit from early, more aggressive treatments as well as those who are likely to be cured by standard methods.
Scientists discover autoimmune disease associated with testicular cancer [Mayo Clinic] In addition to identifying the cause of this mysterious neurological disease, the results point the way to using this protein biomarker as a diagnostic test for men with testicular cancer-associated paraneoplastic encephalitis.
	4.2 DÉP., DIAG. & PRONO. - GÉNOME
Simpler name for cancer genetic syndrome could save lives [University of Washington] A new name would also improve communication about the syndrome with patients and the public. Pritchard believes that it could help people realize that the cancer risk syndrome occurs in all sexes, can be inherited along either the father’s or the mother’s side of the family, and that the cancer risk is not confined to the breasts or the ovaries.
	5. TRAITEMENTS
Navigating the AML Treatment Algorithm in Era of Targeted Rx [Clinical Oncology News] Over the past two years, eight novel targeted agents have been added to the treatment arsenal for acute myeloid leukemia (AML), making treatment algorithms a bit more complex than the “7+3” chemotherapy induction regimen that has been around for more than 40 years.
	5.1 TRAITEMENTS - PRÉ-CLINIQUE
Treatment target pinpointed for liver cancer in young adults [University of Washington] New findings show how a genetically aberrant, fused protein promotes a rare form of liver cancer in adolescents and young adults. The researchers also saw that a certain mix of drugs could target the fused protein and the enzymes that it recruits. In the lab, this drug combination slowed down the uncontrolled growth of cells carrying the liver cancer mutation.
	5.12.4 IMMUNOTHÉRAPIES - ESSAIS
Strain of common cold virus could revolutionise treatment of bladder cancer [ecancer news] A strain of the common cold virus has been found to potentially target, infect and destroy cancer cells in patients with bladder cancer, a new study in the medical journal Clinical Cancer Research reports.
Common cold virus could cure cancer, pioneering trial suggests [The Telegraph] Prov Pandha said: “It’s almost like a universal agent - once it gets in it kills the cancer. It could be combined with lots of other treatments.”
Bladder cancer 'attacked and killed by common cold virus' [BBC News] In this study, 15 patients with the disease were given the cancer-killing coxsackievirus (CVA21) through a catheter one week before surgery to remove their tumours. "The virus gets inside cancer cells and kills them by triggering an immune protein - and that leads to signalling of other immune cells to come and join the party."
	5.12.8 IMMUNOTHÉRAPIES - ECONOMIE
New skin cancer immunotherapy added to NHS England’s Cancer Drugs Fund [Cancer Research UK] Cancer Research UK’s Rose Gray said the National Institute for Health and Care Excellence’s (NICE) recommendation of cemiplimab (Libtayo) was significant. The drug will be used to treat adults with an advanced form of skin cancer called cutaneous squamous cell carcinoma (CSCC) when surgery or radiotherapy to cure their cancer aren’t an option.
	5.3 TRAITEMENTS - FDA, EMA, NICE...
Clinical trial sponsors called to publish results on EU database [European Pharmaceutical Review] The reporting compliance of non-commercial sponsors was much lower than for commercial sponsors, with 23.6 percent of results posted for non-commercial sponsors versus 77.2 percent for commercial sponsors, therefore EU authorities are taking various steps to ensure sponsors are aware of their obligations and can act on them.
Medicine shortages: EU network takes steps to improve reporting and communication [EMA] Both documents lay the foundations for an improved and harmonised EU approach in reporting of and communication on medicines’ shortages and availability issues, a key public health priority for the EU network.
	5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
FDA approves multiple myeloma therapy Xpovio despite safety concerns [Pharmafile] 27% of the 202 participants across the whole trial were forced to discontinue treatment due to adverse reactions, while the rate of fatal adverse reactions was 8.9%.
Informed Consent Application for Azacitidine Celgene Received a Positive Opinion from the EMA [ESMO] Marketing authorisation granted for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
	5.4 TRAITEMENTS - ECONOMIE
One lung cancer drug receives NHS England approval, while another is rejected [Cancer Research UK] The two drugs – dacomitinib (Vizimpro) and osimertinib (Tagrisso) – were each being considered as initial treatments for patients whose non small cell lung cancer (NSCLC) had begun to spread to other parts of the body. Patients’ cancer cells would also need to test positive for a faulty version of a molecule called EGFR.
Life-extending lung cancer treatment recommended for use on the NHS [NICE] Dacomitinib has been recommended as a first-line treatment option for people with a type of non-small-cell lung cancer (NSCLC), in new NICE guidance. This is a change from the committee’s initial decision which found dacomitinib to not be a cost-effective use of NHS resources.
NICE recommends Pfizer's Vizimpro, rejects AstraZeneca's Tagrisso, in non-small cell lung cancer [Pharmafile] The recommendation, made after the manufacturer agreed to a confidential discount, will make the drug available on the health service specifically in locally advanced or metastatic NSCLC, that has tested positive for the epidermal growth factor receptor (EGFR) mutation. It is thought that around 1,477 patients will be eligible to receive the drug per year.
	6.4 MÉDICO-ÉCO
Price Transparency in Health Care Is Coming to the U.S. — But Will It Matter? [Harvard Business Review] Health care is a really strange economic sector, and it doesn’t always follow the usual rules.
Will price transparency reduce prices? [Healthcare Economist] The ultimate result of price transparency is unknown. As the authors of the HBR article state, expectations should be tempered that price transparency will lead to a dramatic change in health care costs, at least in the short-run.